Internal medicine journal
Cure8 research brief
Why This Matters
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and moderate long-term persistence, information useful when discussing management options.
Who Should Pay Attention
Patients on infliximab, adalimumab, or vedolizumab who are experiencing loss of response; clinicians managing biologic dosing; researchers interested in real-world biologic outcomes.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This retrospective cohort study (2018–2024) examined outcomes after dose escalation of infliximab, adalimumab, or vedolizumab for secondary loss of response in 155 people with IBD (mostly Crohn's). Escalation was often done for secondary loss of response and low drug concentrations.
Infliximab and adalimumab dose increases were associated with sustained improvements in clinical scores and some biomarker reductions; vedolizumab improvement was seen at 3 months only. Treatment persistence at 36 months ranged from ~58–73%. Nine patients had minor adverse events.
The report summarizes real-world, single-centre retrospective data rather than a randomized trial. It supports that dose escalation can regain clinical response for many patients and that persistence varies by agent. Discussing escalation alongside drug-level testing appears relevant, but individual decisions should be made with a clinician.
This brief is grounded in the article abstract provided and does not reflect review of a full journal article beyond that abstract.
Keep In Mind
This is a retrospective single-centre cohort using data from 2018–2024; results may reflect local practice patterns and are not randomized evidence. ‘Dose escalation’ and reasons (secondary loss of response, low drug levels) were common but the study design limits causal conclusions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternal medicine journal
AuthorsFaris Gondal, Maddison Terlato, Omar Salehi +6 more
InstitutionDepartment of Gastroenterology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 16, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Escalating Crohn's Care: The Case for Dual Therapy - Medscape
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Escalating Crohn’s Care: The Case for Dual Therapy
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.